Novel therapeutic agents for the treatment of diabetic kidney disease

Expert Opin Investig Drugs. 2020 Nov;29(11):1277-1293. doi: 10.1080/13543784.2020.1811231. Epub 2020 Sep 14.

Abstract

Introduction: Diabetic kidney disease (DKD) involves multifaceted pathophysiology which increases the risk of cardiorenal events and mortality. Conventional therapy is limited to renin-angiotensin aldosterone system inhibition and management of hyperglycemia and hypertension. Recent clinical trials have demonstrated promising nephroprotective effects of antihyperglycemic agents thus modifying guideline treatment recommendations for type 2 diabetic patients with chronic kidney disease.

Areas of covered: Relevant studies and clinical trials were searched via PubMed and clinicaltrials.gov through August 2020. Authors offer an update on clinical evidence regarding nephroprotective effects and side effects of sodium-glucose-cotransporter-2 (SGLT2) inhibitors, glucagon-like-peptide-1 (GLP1) agonists and dipeptidylpeptidase-4 (DPP4) inhibitors. They discuss the potential benefits of novel therapy targeting DKD pathogenic processes including inflammation, oxidative stress, fibrosis, and vasoconstriction shown in early phases of clinical trials and offer an opinion on key challenges and directions for future progress.

Expert opinion: SGLT2 inhibitors are the most promising agents for DKD and improving cardiorenal outcomes. Mineralocorticoid-receptor antagonists and janus kinase inhibitors are also promising investigational therapies that target oxidative stress, nitric oxide synthesis, and inflammation. Novel therapeutic targets and the identification of clinically useful biomarkers may provide future therapies that detect early stages of DKD enabling a slower kidney function decline.

Keywords: Renal disease; albuminuria; diabetic kidney disease; glomerular filtration rate; investigational agents; novel drugs.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / physiopathology
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Drugs, Investigational / pharmacology
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Nitric Oxide / metabolism
  • Oxidative Stress / drug effects
  • Renin-Angiotensin System / drug effects
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Drugs, Investigational
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • Nitric Oxide